Last reviewed · How we verify

Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease

NCT03862274 ENROLLING_BY_INVITATION

The investigators propose a study to assess cognitive and developmental outcomes of patients with CLN2 that are untreated and receiving cerliponase alfa. This study aims to validate standardized assessment measures to establish a standard of care. The secondary aim is to compare cognitive and developmental outcomes of patients with CLN2 that are receiving celiponase alfa to a natural history cohort. To accomplish specific aims of the study, the investigators will use a multi-method approach to collect retrospective data collected as standard of care and prospective developmental data in children with CLN2 disease. The investigators will use a combination of standardized measures that include direct assessment and parent report of child development. The investigators focus will also include multiple measures of development including language, motor, social-emotional, and adaptive functioning.

Details

Lead sponsorJessica Scherr
StatusENROLLING_BY_INVITATION
Enrolment30
Start date2018-12-01
Completion2025-12

Conditions

Interventions

Primary outcomes

Countries

United States